Diet and stress effects on omalizumab response in chronic hives
Part of Immune system & allergy, Skin clinical trials.
This study looks at how diet and oxidative stress (a type of cell damage) affect the severity of chronic hives and how well patients respond to the medication omalizumab (Xolair). It may help find ways to improve treatment by understanding these factors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with chronic spontaneous urticaria (ongoing hives for at least 6 weeks).
- You do not have any other major health conditions like diabetes, inflammatory diseases, or cancer.
- You have not used anti-inflammatory drugs or medications that affect blood sugar or cholesterol in the last 3 months.
- You are not a smoker or regular alcohol drinker, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a bacterial extract called OM-85 to your usual antihistamine helps control chronic hives better than antihistamines alone. It is an observational study, meaning the treatment is decided by your doctor, not assigned randomly.
This study follows patients with severe asthma or chronic hives who are already on omalizumab (Xolair) and are switching to a very similar, lower-cost biosimilar called OMLYCLO. It aims to see if the switch works well in real-world practice.
This trial tests a new injection (CM512) for people with chronic spontaneous urticaria, also known as chronic hives. If you have had itchy hives for at least 6 weeks despite taking regular antihistamines, this study may help find a new treatment option.
This trial tests a new oral medication for chronic spontaneous urticaria (chronic hives). It is a placebo-controlled study, meaning some participants will get the new drug and some will get a placebo (a pill with no active ingredient). The goal is to see if the new drug is safe and how well it works, possibly providing a new treatment option for those whose hives are not controlled by current antihistamines.
This study tests a new oral medication (TLL-018) for people with chronic hives that don't fully go away with standard antihistamines. It aims to see if the drug reduces itching and hives better than placebo.
This study tests whether following a Mediterranean diet or a low-histamine diet can help reduce symptoms of chronic spontaneous urticaria (hives) in teens. It compares the two diets to see which one might work better for managing this condition.
Hear when a new Chronic Spontaneous Urticaria (CSU) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.